|
|
|
Vascular Endothelial Growth Factor (VEGF) induces angiogenesis, but also disrupts vascular barrier function in diseased tissues. VEGF-mediated pathogenic effects are due to its effects on vascular permeability, resulting in injury to ischemic tissues after stroke or myocardial infarction. In cancer, VEGF-mediated disruption of the vascular barrier may lead to metastatic disease.
|
|
VEGF can reliably be measured with a novel
|
|
Human VEGF ELISA assay
utilizing epitope-mapped recombinant antibodies enabling a highly sensitive and specific quantification of VEGF in various sample types.
Find out more VEGF ELISA
|
|
|
|
3D structure of human VEGF dimer with antibody epitopes:
Recombinant capture antibody – purple
Detection Antibody – blue
|
|
Highlights
• SMALL sample volume – only 10 µl/wellrequired
• HIGH SENSITIVITY – measurable values in both serum AND plasma
• RELIABLE – rigorously validated according to FDA/EMEA/ICH guidelines
• EXCELLENT CORRELATION to existing methods
|
|
|
Check out our Poster: “Highly sensitive quantification of human VEGF with an ELISA”
Review: VEGF in Signaling and Disease: Beyond Discovery and Development. Apte RS et al., Cell. 2019; 176, 6: 1248–64.
|
|
Complete ready to use ELISA kits for superior performance and reproducibility
Related products: human Angiopoietin-2, total soluble Neuropilin-1, Semaphorin 4D
|
|
|
